{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+Instability-High&page=3",
    "query": {
      "condition": "Microsatellite Instability-High",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 84,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+Instability-High&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Microsatellite+Instability-High&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T19:19:24.236Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04116320",
      "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Breast Cancer",
        "Merkel Cell Carcinoma",
        "Squamous Cell Cancer",
        "Non Small Cell Lung Cancer",
        "Cervical Cancer",
        "Urothelial Carcinoma",
        "Ovarian Cancer",
        "Hepatocellular Carcinoma",
        "Small-cell Lung Cancer",
        "Microsatellite Instability High",
        "Gastric Cancer",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "Echopulse",
          "type": "DEVICE"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "Standard of Care PD-1 Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2019-11-21",
      "completion_date": "2023-08-15",
      "has_results": false,
      "last_update_posted_date": "2025-07-14",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04116320"
    },
    {
      "nct_id": "NCT04751370",
      "title": "Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Rectal Adenocarcinoma",
        "Stage II Rectal Cancer AJCC v8",
        "Stage III Rectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Sigmoidoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Total Mesorectal Excision",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2022-02-08",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 213,
      "location_summary": "Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 145 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04751370"
    },
    {
      "nct_id": "NCT04234113",
      "title": "Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Thyroid Cancer",
        "Renal Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Small-cell Lung Cancer",
        "Bladder Cancer",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Skin Squamous Cell Carcinoma",
        "Microsatellite Instability High",
        "Triple Negative Breast Cancer",
        "Mesothelioma",
        "Thymic Cancer",
        "Cervical Cancer",
        "Biliary Tract Cancer",
        "Hepatocellular Carcinoma",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Anal Cancer"
      ],
      "interventions": [
        {
          "name": "Nanrilkefusp alfa",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SOTIO Biotech AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2019-06-13",
      "completion_date": "2024-11-27",
      "has_results": true,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 3,
      "location_summary": "New Haven, Connecticut • Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04234113"
    },
    {
      "nct_id": "NCT06047379",
      "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Astrocytoma, IDH-Mutant",
        "Glioblastoma, IDH-wildtype",
        "Brain Metastases, Adult",
        "Cervical Cancer",
        "Colorectal Cancer",
        "Esophageal Cancer",
        "Esophageal Squamous Cell Carcinoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Melanoma",
        "Merkel Cell Carcinoma",
        "Microsatellite Instability-High Solid Malignant Tumor",
        "Mismatch Repair Deficient Solid Malignant Tumor",
        "Microsatellite Instability-High Colorectal Cancer",
        "Mismatch Repair Deficient Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Renal Cell Carcinoma",
        "Small Cell Lung Cancer",
        "Squamous Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "NEO212 Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI Protocol",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neonc Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 134,
      "start_date": "2023-11-01",
      "completion_date": "2027-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 8,
      "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06047379"
    },
    {
      "nct_id": "NCT04041310",
      "title": "Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "GAd-209-FSP low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GAd-209-FSP high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GAd20-209-FSP, RP2D",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-209-FSP, RP2D",
          "type": "BIOLOGICAL"
        },
        {
          "name": "KEYTRUDA®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nouscom SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2019-10-21",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04041310"
    },
    {
      "nct_id": "NCT03241173",
      "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignancies"
      ],
      "interventions": [
        {
          "name": "INCAGN01949",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Biosciences International Sàrl",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2017-10-09",
      "completion_date": "2019-09-17",
      "has_results": true,
      "last_update_posted_date": "2022-09-27",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03241173"
    },
    {
      "nct_id": "NCT06006923",
      "title": "Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MSI-H Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Regorafenib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anwaar Saeed",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2024-06-26",
      "completion_date": "2025-11-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06006923"
    },
    {
      "nct_id": "NCT06710847",
      "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Colorectal",
        "Solid Tumor",
        "Colon Cancer",
        "Rectal Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "GSK4418959",
          "type": "DRUG"
        },
        {
          "name": "PD-1 inhibitor",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2024-12-13",
      "completion_date": "2026-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Denver, Colorado • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06710847"
    },
    {
      "nct_id": "NCT03126110",
      "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignancies",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "INCAGN01876",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Biosciences International Sàrl",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 145,
      "start_date": "2017-04-25",
      "completion_date": "2021-11-09",
      "has_results": true,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03126110"
    },
    {
      "nct_id": "NCT04458259",
      "title": "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "PF-07265807",
          "type": "DRUG"
        },
        {
          "name": "Sasanlimab",
          "type": "DRUG"
        },
        {
          "name": "Axitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2020-09-24",
      "completion_date": "2024-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-08T19:19:24.236Z",
      "location_count": 25,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04458259"
    }
  ]
}